Genomic features of exceptional response in vemurafenib ± cobimetinib–treated patients with BRAF(V600)-mutated metastatic melanoma

PURPOSE: Previous investigations identified transcriptional signatures associated with innate resistance to anti–programmed cell death protein 1 therapy in melanoma. This analysis aimed to increase understanding of the role of baseline genetic features in the variability of response to BRAF and MEK...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Clin Cancer Res
Asıl Yazarlar: Yan, Yibing, Wongchenko, Matthew J., Robert, Caroline, Larkin, James, Ascierto, Paolo A., Dréno, Brigitte, Maio, Michele, Garbe, Claus, Chapman, Paul B., Sosman, Jeffrey A., Shi, Zhen, Koeppen, Hartmut, Hsu, Jessie J., Chang, Ilsung, Caro, Ivor, Rooney, Isabelle, McArthur, Grant A., Ribas, Antoni
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2019
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC8083896/
https://ncbi.nlm.nih.gov/pubmed/30824584
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-18-0720
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller